In another phase II trial (TANDEM), CVC was combined with Tropifexor, a farnesoid X receptor agonist (FXR), for the improvement of hepatic fibrosis in the same category of patients, although the analysis of results is still ongoing [45]. This evidence concerns the gene NR1H4 and Hepatic fibrosis.